西特罗内拉尔通过影响GCH1蛋白的稳定性来改善内皮功能障碍
Yaqi Guo1, Huadong Que1, Bulei Chen1
1SanQuan Medical College, Sino-UK Joint Laboratory of Brain Function and Injury and Department of Physiology and Neurobiology, Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, School of Basic Medical Sciences, College of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China.
Acta biochimica et biophysica Sinica
|July 12, 2024
概括
Smad-ubiquitination调节因子2 (Smurf2) 针对瓜诺辛三酸环罗1 (GCH1) 的降解,加剧了内皮功能障碍. 烯拉 (CT) 改善了这种损伤,表明了夫2-GCH1相互作用作为治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子细胞生物学 分子细胞生物学
- 生物化学 生物化学
背景情况:
- 内皮功能障碍 (ED) 是心血管疾病的基础,与关三酸环罗1 (GCH1) 的氧化物 (NO) 生产受损有关.
- 氧化应激降解GCH1,恶化ED,而青 (CT) 则显示出改善动脉样硬化引起的ED的前景.
- 在GCH1调节中,无素的作用以及涉及的特定E3结合酶的作用仍然不清楚.
研究的目的:
- 研究Smad-ubiquitination调节因子2 (Smurf2) 在GCH1降解中的作用及其对内皮功能障碍的贡献.
- 探索CT在逆转与1型糖尿病 (T1DM) 相关的ED的治疗潜力.
- 为了阐明将Smurf2,GCH1和内皮细胞功能联系在一起的分子机制.
主要方法:
- 数据库的探索,以确定Smurf2和GCH1水平之间的相关性.
- 同免疫沉试验证实了小松鼠2-GCH1相互作用.
- 使用HUVEC的体外研究和使用T1DM大鼠模型的体内研究.
主要成果:
- Smurf2 直接与 GCH1 相互作用,并促进其蛋白质体降解,与 GCH1 水平负相关.
- 异胎性Smurf2表达减少了GCH1水平,细胞增殖,并增加了活性氧物种 (ROS).
- 在T1DM大鼠中,CT治疗改善了血管内皮损伤,并逆转了改变的GCH1和Smurf2表达.
结论:
- 松鼠2介导的GCH1的泛化和蛋白质体降解是驱动内皮功能障碍的关键机制.
- 蝶2-GCH1相互作用代表了心血管疾病和内皮损伤的潜在治疗标.
- 电脑图像扫描在改善内皮功能方面表现出有效性,很可能是通过调节Smurf2-GCH1通路.
相关概念视频
01:28Nitric Oxide Signaling Pathway
5.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
74
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
74
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
600
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
600
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419